TSCAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.68 USD | +4.92% |
|
+5.79% | +31.73% |
| Apr. 19 | TScan Therapeutics Closes $150.1 Million Securities Offering | MT |
| Apr. 17 | TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 106.9 | 37.32 | 278.8 | 368.8 | - | - |
| Enterprise Value (EV) 1 | -54.48 | -53.41 | 116.8 | 299.9 | 302 | 368.8 |
| P/E ratio | -1.08 x | -0.56 x | -4.29 x | -7.12 x | -6.48 x | -6.17 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 10.5 x | 2.76 x | 13.2 x | 21 x | 23.5 x | 29.1 x |
| EV / Revenue | -5.37 x | -3.95 x | 5.55 x | 17 x | 19.3 x | 29.1 x |
| EV / EBITDA | 1.27 x | 0.94 x | -1.41 x | -2.77 x | -2.33 x | - |
| EV / FCF | 0.93 x | 0.76 x | -1.81 x | -3.13 x | -2.81 x | -3.64 x |
| FCF Yield | 108% | 132% | -55.2% | -31.9% | -35.6% | -27.5% |
| Price to Book | - | 0.37 x | 1.85 x | 4.98 x | 8.51 x | - |
| Nbr of stocks (in thousands) | 23,761 | 24,080 | 47,825 | 50,377 | - | - |
| Reference price 2 | 4.500 | 1.550 | 5.830 | 7.320 | 7.320 | 7.320 |
| Announcement Date | 3/9/22 | 3/8/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10.14 | 13.54 | 21.05 | 17.6 | 15.66 | 12.67 |
| EBITDA 1 | - | -42.8 | -56.95 | -82.89 | -108.1 | -129.5 | - |
| EBIT 1 | - | -48.64 | -66.64 | -93.46 | -107.9 | -125.1 | -137.5 |
| Operating Margin | - | -479.65% | -492.32% | -444% | -613.35% | -798.94% | -1,085.82% |
| Earnings before Tax (EBT) 1 | - | -48.62 | -66.22 | -89.22 | -99.16 | -119.2 | -143.9 |
| Net income 1 | -26.13 | -48.62 | -66.22 | -89.22 | -103.4 | -119.3 | -128.3 |
| Net margin | - | -479.49% | -489.26% | -423.86% | -587.81% | -761.68% | -1,012.74% |
| EPS 2 | -3.480 | -4.170 | -2.750 | -1.360 | -1.028 | -1.130 | -1.187 |
| Free Cash Flow 1 | - | -58.62 | -70.73 | -64.5 | -95.76 | -107.7 | -101.4 |
| FCF margin | - | -578.03% | -522.56% | -306.45% | -544.14% | -687.44% | -800.4% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/19/21 | 3/9/22 | 3/8/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.412 | 2.854 | 3.021 | 4.056 | 3.363 | 3.096 | 6.803 | 3.148 | 3.887 | 7.211 | 4.3 | 4.421 | 4.584 | 4.713 | 2.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -15.84 | -14.2 | -16.16 | -15.25 | -16.58 | -18.65 | -22.74 | -24.61 | -24.75 | -21.36 | -25.37 | -26.36 | -27.56 | -28.64 | - |
| Operating Margin | -656.8% | -497.62% | -535.02% | -375.89% | -492.95% | -602.33% | -334.31% | -781.77% | -636.69% | -296.17% | -590.02% | -596.33% | -601.37% | -607.74% | - |
| Earnings before Tax (EBT) 1 | -15.84 | -14.2 | -16.16 | -15.1 | -16.24 | -18.72 | -22.56 | -24.04 | -23 | -19.61 | -23.91 | -24.31 | -25.27 | -25.67 | - |
| Net income 1 | -15.84 | -14.2 | -16.16 | -15.1 | -16.24 | -18.72 | -22.56 | -24.04 | -23 | -19.61 | -24.45 | -25.28 | -26.41 | -27.3 | - |
| Net margin | -656.67% | -497.55% | -534.79% | -372.21% | -483.05% | -604.75% | -331.66% | -763.82% | -591.64% | -271.99% | -568.69% | -571.77% | -576.25% | -579.32% | - |
| EPS 2 | -0.8000 | -0.5900 | -0.6700 | -0.6300 | -0.6700 | -0.7800 | -0.9300 | -0.5100 | -0.2400 | -0.1100 | -0.2533 | -0.2433 | -0.2567 | -0.2667 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/9/22 | 5/9/22 | 8/10/22 | 11/9/22 | 3/8/23 | 5/10/23 | 8/10/23 | 11/9/23 | 3/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 161 | 90.7 | 162 | 68.9 | 66.7 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -58.6 | -70.7 | -64.5 | -95.8 | -108 | -101 |
| ROE (net income / shareholders' equity) | - | - | -50.9% | -71.3% | -84.3% | -124% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.130 | 3.150 | 1.470 | 0.8600 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 9.94 | 4.23 | 3.15 | - | - | - |
| Capex / Sales | - | 98.03% | 31.22% | 14.95% | - | - | - |
| Announcement Date | 3/19/21 | 3/9/22 | 3/8/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.32
USD
Average target price
11.6
USD
Spread / Average Target
+58.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.73% | 369M | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- TCRX Stock
- Financials TScan Therapeutics, Inc.
